Sinopharm Group (SHTDF) Stock Price, News & Analysis

Company Overview

Sinopharm Group Co., Ltd is one of China’s largest state-owned integrated healthcare companies, primarily focused on the research, development, production and distribution of a broad range of pharmaceutical and healthcare products. Established in 1998 through the reorganization of assets under China National Pharmaceutical Group (Sinopharm), the company has grown to encompass multiple business segments, including prescription medicines, over-the-counter drugs, vaccines and medical devices. Sinopharm Group is listed on the Hong Kong Stock Exchange and trades in the United States through its OTCMKTS ticker SHTDF.

The company’s product portfolio spans chemically synthesized drugs, biologics and traditional Chinese medicine formulations, supported by an extensive nationwide manufacturing and quality-control network. Sinopharm Group is also a major supplier of vaccines in China, delivering both routine immunizations and emergency-use vaccines, including its COVID-19 portfolio. In addition to pharmaceutical R&D and production, the company operates a network of retail pharmacies and provides logistics, cold-chain distribution and hospital procurement services, enabling it to serve hospitals, clinics and end-users across the healthcare value chain.

Headquartered in Beijing, Sinopharm Group has built a presence throughout mainland China via regional subsidiaries and distribution centers, and it has progressively expanded its international footprint through export partnerships and joint ventures in Asia, Africa and Latin America. Leveraging its state-backed heritage and broad operational scope, the company continues to focus on advancing innovation, strengthening its supply capabilities and collaborating with global health organizations to address public health needs at home and abroad.

Key Stats

• Today's Range: $2.35 to $2.35
• 50-Day Range: $2.30 to $2.68
• 52-Week Range: $2.11 to $2.70
• Volume: N/A
• Average Volume: 20,516 shs
• Market Capitalization: N/A
• P/E Ratio: 2.35
• Dividend Yield: 11.06%
• Price Target: N/A
• Consensus Rating: N/A

Sinopharm Group Stock Analysis - MarketRank™

Sinopharm Group scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Sinopharm Group.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Sinopharm Group is 2.35, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.39.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sinopharm Group is 2.35, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 20.79.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Sinopharm Group has a short interest ratio ("days to cover") of 999.99, which indicates bearish sentiment.

Change versus previous month

Short interest in Sinopharm Group has recently increased by 269.23%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Sinopharm Group pays a meaningful dividend of 1.11%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Sinopharm Group does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Sinopharm Group is 26.05%. This payout ratio is at a healthy, sustainable level, below 75%.

News and Social Media

• Score: 1.4 / 5
• News Sentiment: N/A

News Sentiment

Sinopharm Group has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sinopharm Group insiders have not sold or bought any company stock.

Percentage Held by Institutions

16.47% of the stock of Sinopharm Group is held by institutions.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Medical Distribution
• Sub-Industry: Personal Services
• Current Symbol: OTCMKTS:SHTDF
• CIK: 1556605
• Web: ir.sinopharmgroup.com.cn
• Phone: 86-21-2305-2666
• Fax: N/A
• Employees: 115,959
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 2.35
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A